All News
RA-ILD in the Spotlight at ACR 2024
Over the past 5 years, there has been growing interest in RA-ILD due to its relative prevalence and severity. This seems to be one of the few RA outcomes not improving much, even with the advent of expanded treatment options. There is also a shocking lack of trial data. This year, there were two oral sessions dedicated to RA-ILD, one of which even the overflow room was standing room only, in addition to many posters.
Read Article
What Lies Beneath: Understanding Nailfold Capillaroscopy
Capillaroscopy is a non-invasive imaging technique used for the in vivo assessment of the microcirculation. kin capillaries at the nailfold are evaluated because the fingers are involved in pathological processes such as Raynaud’s phenomenon. Several abstracts and sessions on nailfold capillaroscopy were presented during ACR24.
Read Article
Maximizing DMARDs to Strive for Steroid-Free Remission in RA
In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).
Read Article
Cyclophosphomide vs Mycophenolate vs Tacrolimus in Lupus Nephritis
Dr. Mike Putman discusses abstract 0670, presented at #ACR24.
https://t.co/aLzsSSOmML https://t.co/XrEtNZAgHI
Dr. John Cush RheumNow ( View Tweet)
SELECTing the right patients: upadacitinib in GCA
Dr. Brian Jaros reports on abstract 1695, presented at #ACR24.
https://t.co/x8lLTviOKk https://t.co/yXwwrdgIyu
Dr. John Cush RheumNow ( View Tweet)
Assessment of axSpA
Dr. Antoni Chan reviews abstracts 0818 and 0819, presented at #ACR24.
https://t.co/2qI6DnnflP https://t.co/BuTdnlMfxq
Dr. John Cush RheumNow ( View Tweet)
PsA Ultrasound Updates
Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR24.
https://t.co/DZBe8uNpJS https://t.co/wIS1hUZnAS
Dr. John Cush RheumNow ( View Tweet)
#ACR Best 2024 - Day 4
Although the last day of #ACR24 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today. As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.… https://t.co/ws9BOxkZft https://t.co/trMevuvvyX
Dr. John Cush RheumNow ( View Tweet)
Methotrexate to Prevent RA, Clear as Mud
Intervention in individuals predisposed to rheumatoid arthritis (RA), aiming for prevention, is a significant topic. Seropositivity for rheumatoid factor and ACPA can precede RA by years. Some patients experience a pre-RA arthralgia… https://t.co/D51CoZAzce https://t.co/lgZalnDeb3
Dr. John Cush RheumNow ( View Tweet)
Predicting flares in rheumatic diseases with machine learning
Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.… https://t.co/6oFRp0zyBw https://t.co/fcMrJOg4mM
Dr. John Cush RheumNow ( View Tweet)
Changing Mindsets about Methotrexate Side Effects
Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24.
https://t.co/8RXBWUioee https://t.co/liQ1hN4Xtr
Dr. John Cush RheumNow ( View Tweet)
How New Medications are Reframing Imaging Abnormalities in axSpA
Bimekizumab (BKZ), a monoclonal antibody targeting IL-17A and IL-17F, was evaluated in the BE MOBILE 1 and 2 trials for non-radiographic and radiographic axSpA, respectively. It showed significant clinical… https://t.co/wJYh5XCVfw https://t.co/qZ2MnGVXXG
Dr. John Cush RheumNow ( View Tweet)
Where there’s smoke, there’s flare: how pollution fuels RA
The WHO has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 #ACR24
https://t.co/efVzSHXN91 https://t.co/AxRyGpqQFa
Dr. John Cush RheumNow ( View Tweet)
Say Goodbye to Methotrexate in PMR?
Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24
https://t.co/x662FbdNoR https://t.co/uvMPHpmRHZ
Dr. John Cush RheumNow ( View Tweet)
Beyond the Needle: Redefining the Assessment of Lupus Nephritis
Lupus nephritis is one of the most silent and severe manifestations of systemic lupus erythematosus (SLE).
https://t.co/JD6z4VTfJn
#ACR24 https://t.co/7gEK8acRl0
Dr. John Cush RheumNow ( View Tweet)
💊Litifilimab- another new molecule for SLE
Anti BDCA2 🎯
In cutaneous lupus👉
👉Decrease CLASI score
👉Decrease IFN induced MxA expression
#ACR2024 #ACRAmbassador https://t.co/AeJOGhVXIR
Ritasman Baisya RitasmanB ( View Tweet)
🌟IgG4RD: Lessons from the first 20 years🌟by Prof John Stone
⭐️Lesson 1- IgG4RD is a variable vessel vasculitis
✨Can cause small vessel vasculitis of the skin
✨One of few vasculitis causing coronary arteritis in adults
⭐️Lesson 2- IgG4RD is more common and severe in males… https://t.co/PvFXyOl5bp https://t.co/hAMelBoZvB
Links:
Darpan Thakare darpan06T ( View Tweet)
Differential diagnosis of ACA+
1. SSc
2. Sjogren Syndrome
3. PBC
4. Overalp syndrome https://t.co/JmqDaaZerJ
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
⏩Lecture by Prof Takeuchi on Sjogren Syndrome. Anti-centromere ab is seen in 10% of primary Sjogren syndrome. more likely to have sclerodactyly. https://t.co/mVry2OaNmq @IRACON24Blr https://t.co/SZlWQDpx8B
Links:
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
New #OAC #BasicScience
This work by Shakya et al. found that basic calcium phosphate crystals are almost exclusively found in menisci from OA patients, while calcium pyrophosphate has similar prevalence in menisci from subjects with and without OA.
🔗 : https://t.co/PBaVQSspiE https://t.co/ivOOKVIX9b
Links:
Osteoarthritis and Cartilage Journals OACJournal ( View Tweet)
